Financial Performance - The company's operating revenue for the first half of 2024 reached ¥24,756,503,031.47, representing a 2.55% increase compared to ¥24,140,175,654.64 in the same period last year[15]. - Net profit attributable to shareholders of the listed company was ¥1,000,510,723.10, up 1.62% from ¥984,583,170.50 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was ¥1,003,099,657.16, reflecting a 5.46% increase from ¥951,127,923.58 year-on-year[15]. - Basic earnings per share for the first half of 2024 were ¥1.3261, a 1.62% increase from ¥1.3049 in the same period last year[16]. - The company's revenue for the reporting period was approximately ¥24.76 billion, representing a year-on-year increase of 2.55% compared to ¥24.14 billion in the same period last year[36]. - The operating costs increased to approximately ¥23.00 billion, reflecting a year-on-year rise of 3.27% from ¥22.27 billion[36]. - The company reported a significant increase in long-term equity investments to CNY 1.77 billion, up from CNY 1.73 billion, representing a growth of approximately 2.0%[106]. - The company reported a total of ¥10,027,885,366.64 in accounts receivable, with a 100% provision method applied based on credit risk characteristics[199]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥33,553,839,547.67, a 3.39% increase from ¥32,453,092,592.42 at the end of the previous year[15]. - The company's total liabilities reached CNY 15.61 billion, up from CNY 14.92 billion, which is an increase of about 4.6%[107]. - Cash and cash equivalents decreased to CNY 8.62 billion from CNY 10.93 billion, a decline of about 21%[105]. - The total liabilities of the company at the end of June 2024 were approximately 1,721.06 million RMB, indicating a manageable debt level[125]. Cash Flow - The company reported a net cash flow from operating activities of -¥1,065,978,344.08, compared to -¥166,057,140.22 in the previous year, indicating a significant decline[15]. - The company reported a net increase in cash and cash equivalents of negative CNY 2.32 billion, compared to negative CNY 1.08 billion in the previous year[119]. - The cash flow from operating activities was approximately ¥24.95 billion, an increase from ¥24.26 billion in the previous year, showing a growth of 2.9%[116]. Investments and Capital - The company invested a total of RMB 1.5 billion in the Guoyao Zhongjin Medical Industry Fund, with RMB 1.22 billion paid as of June 30, 2024[43]. - The company has not yet made any investments in the hospital supply chain extension project, community hospital pharmacy management project, or hospital cold chain logistics system construction project, all of which have a planned investment amount of 65,057.95 million CNY, 12,378.20 million CNY, and 20,285.83 million CNY respectively[95]. - The company completed a private placement of 41,365,452 shares at RMB 24.90 per share, raising a net amount of approximately RMB 1.018 billion for asset acquisition[132]. Risk Management - There are no significant risk events reported during the reporting period, and potential risks have been detailed in the management discussion section[4]. - The company faces risks from policy changes affecting drug pricing and reimbursement, impacting profit margins in the pharmaceutical distribution sector[47]. - The company is focusing on enhancing compliance management to mitigate risks, with ongoing improvements to its internal control systems[34]. Market Position and Strategy - The company achieved 100% coverage of grade hospitals in Beijing and over 4,700 grassroots medical institutions, maintaining a leading sales position in secondary and tertiary hospitals[21]. - The company is focusing on transforming its service model from pure drug sales to providing comprehensive pharmaceutical solutions[29]. - The pharmaceutical industry is experiencing a slowdown in market growth due to ongoing reforms and cost control measures, presenting both challenges and opportunities for the company[20]. Environmental and Social Responsibility - The company has established eight pollution prevention facilities in accordance with national environmental protection standards, ensuring stable operation[54]. - The company has engaged in poverty alleviation and rural revitalization efforts, purchasing local agricultural products to support local farmers[69]. - The company reduced carbon emissions by a total of 498 tons through various measures, including intelligent control of refrigeration units and the replacement of high-energy-consuming pumps[69]. Corporate Governance - The company appointed Meng Jianyun as the employee supervisor, replacing Yang Chunyu who left due to job relocation[50]. - The company has not reported any major guarantees or significant contracts during the reporting period[91][92]. - The company has been managing related party transactions effectively, with all transactions in the first half of 2024 falling within the expected amounts[80]. Accounting Policies - The company's financial statements are prepared based on the going concern principle in accordance with the accounting standards issued by the Ministry of Finance[135]. - The company recognizes revenue when control of goods or services is transferred to customers, typically at the point of customer acceptance[171]. - The company applies expected credit loss measurement for accounts receivable over the entire duration, regardless of significant financing components[200].

证券代码：600511 证券简称：国药股份 公告编号：临 2024-028 国药集团药业股份有限公司关于 2024 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金及到账情况 经中国证券监督管理委员会于 2017 年 2 月 16 日签发的《关于核准国药集团药业股份 有限公司向国药控股股份有限公司等发行股份购买资产并募集配套资金的批复》(证监许可 [2017]219 号）核准，国药集团药业股份有限公司(以下简称"本公司""公司")获准向国 药控股股份有限公司发行 212,736,835 股股份、向北京畅新易达投资顾问有限公司发行 11,990,013 股股份、向北京康辰药业股份有限公司发行 20,075,116 股股份购买相关资产， 同时核准公司向境内特定投资者非公开发行不超过 41,035,851 股新股募集本次发行股份购 买资产的配套资金。公司实际非公开发行人民币普通股 41,365,452 股，每股面值人民币 1 元，每股发行价格为人民 ...

证券代码：600511 证券简称：国药股份 公告编号：临 2024-027 （一）以 3 票同意、0 票反对和 0 票弃权的结果审议通过《国 药股份 2024 年半年度报告全文及摘要的议案》。 经核查，监事会认为：公司 2024 年半年度报告的编制和审 议程序符合相关法律、法规及《公司章程》等内部规章制度的规 定；公司 2024 年半年度报告的内容与格式符合相关规定，公允 1 地反映了公司 2024 半年度的财务状况和经营成果等事项；半年 度报告编制过程中，未发现公司参与半年度报告编制和审议的人 员有违反保密规定的行为；监事会全体成员保证公司 2024 年半 年度报告披露的信息真实、准确、完整，不存在任何虚假记载、 误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性 依法承担法律责任。 内容详见上海证券交易所网站 www.sse.com.cn 同日披露的 国药股份 2024 年半年度报告全文及摘要。 国药集团药业股份有限公司 第八届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任 何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 一、监事会会 ...

证券代码：600511 证券简称：国药股份 公告编号：临 2024-022 国药集团药业股份有限公司 关于增加 2024 年日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任 何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 重要内容提示： 该议案尚需提交股东大会审议。 易相关内容进行了单独公告。（公告内容详见 2024 年 3 月 21 日 刊登于《上海证券报》《中国证券报》《证券日报》《证券时报》 和上海证券交易所网站上的《国药集团药业股份有限公司关于 2023 年日常关联交易情况和预计 2024 年日常关联交易的公告》 【临 2024-006】）。 公司预计增加的 2024 年度日常关联交易为日常经营需 要，不存在损害公司和非关联方股东利益的情形，不影响公司独 立性。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 国药集团药业股份有限公司（以下简称"公司"）独立董事 2024 年第一次专门会议、第八届董事会第十五次会议、第八届 监事会第十一次会议、2023 年年度股东大会审议通过了《国药 股份 2023年日常交易情况和预计 202 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 12,122,142,562.33, representing a year-on-year increase of 7.98%[4] - The net profit attributable to shareholders for Q1 2024 was CNY 459,454,518.02, reflecting a growth of 10.86% compared to the same period last year[4] - The basic earnings per share for Q1 2024 was CNY 0.6089, which is an increase of 10.86% year-on-year[5] - The net profit for Q1 2024 was CNY 495,118,467.38, which is an increase of 9.9% from CNY 450,409,271.64 in Q1 2023[19] - The profit attributable to shareholders of the parent company for Q1 2024 was CNY 459,454,518.02, compared to CNY 414,409,175.82 in Q1 2023, reflecting a growth of 10.9%[19] - The total comprehensive income for Q1 2024 was ¥309,812,727.18, compared to ¥283,206,166.14 in Q1 2023, indicating an increase of 9.4%[25] Cash Flow - The net cash flow from operating activities for Q1 2024 was negative at CNY -1,719,799,376.67, indicating a significant cash outflow[4] - The cash inflow from operating activities totaled ¥5,539,406,936.00 in Q1 2024, compared to ¥5,368,466,798.45 in Q1 2023, showing a growth of 3.2%[26] - The cash flow from operating activities showed a net outflow of ¥301,387,089.18 in Q1 2024, compared to a net inflow of ¥78,555,396.09 in Q1 2023[26] - The net cash outflow from operating activities was ¥1.72 billion in Q1 2024, compared to a net outflow of ¥1.14 billion in Q1 2023, indicating a worsening cash flow situation[20] - The cash inflow from investment activities was ¥18.65 million in Q1 2024, significantly higher than ¥5.85 million in Q1 2023, showing a substantial increase in investment returns[21] - The net cash outflow from investment activities was ¥2.33 million in Q1 2024, an improvement from a net outflow of ¥15.82 million in Q1 2023, reflecting better investment management[21] - The cash inflow from financing activities totaled ¥338.20 million in Q1 2024, slightly lower than ¥372.03 million in Q1 2023, indicating a decrease in financing activities[21] - The net cash outflow from financing activities was ¥116.58 million in Q1 2024, compared to a net outflow of ¥161.78 million in Q1 2023, showing improved cash management in financing[21] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to CNY 32,919,056,402.95, a slight increase of 1.44% from the end of the previous year[5] - The total liabilities as of the reporting date were CNY 14,898,012,994.93, slightly down from CNY 14,919,938,717.90 in the previous year[16] - The total assets as of the reporting date were CNY 32,919,056,402.95, compared to CNY 32,453,092,592.42 in the previous year, showing an increase of 1.4%[16] - The total current assets were approximately ¥16.99 billion as of March 31, 2024, down from ¥18.17 billion at the end of 2023, reflecting a decline in liquidity[22] - The total liabilities decreased to ¥10,155,730,572.50 in Q1 2024 from ¥11,571,806,815.96 in Q1 2023, a reduction of approximately 12.2%[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,921[8] - The largest shareholder, China National Pharmaceutical Group Co., Ltd., held 54.72% of the shares, totaling 412,841,745 shares[8] - The company reported a total of 211,685,171 shares held by its largest shareholder, China National Pharmaceutical Group, indicating significant ownership concentration[9] Research and Development - Research and development expenses for Q1 2024 were CNY 13,941,626.51, down from CNY 16,684,728.20 in Q1 2023, indicating a decrease of 16.4%[18] - The company's research and development expenses were not specified in the report, indicating a potential area for future disclosure[24] Other Financial Metrics - The company reported non-recurring gains of CNY 1,472,368.63 for the period, after accounting for tax and minority interests[7] - The weighted average return on equity for Q1 2024 was 2.87%[5] - The company reported an investment income of CNY 104,978,672.01 for Q1 2024, up from CNY 80,674,195.75 in Q1 2023, representing a growth of 30.0%[18] - The company's contract liabilities increased significantly to ¥69,816,037.03 in Q1 2024 from ¥8,228,053.18 in Q1 2023, marking a substantial rise of 749.5%[23] Miscellaneous - The report was issued by the board of directors of China National Pharmaceutical Group Corporation on April 25, 2024[29] - The company did not execute any adjustments related to new accounting standards for the first quarter of 2024[29]

Financial Performance - The company's operating revenue for 2023 reached ¥49,696,045,528.87, an increase of 9.23% compared to ¥45,498,583,764.24 in 2022[15] - The net profit attributable to shareholders of the listed company was ¥2,145,998,746.54, reflecting a growth of 9.26% from ¥1,964,057,559.33 in the previous year[15] - The net profit after deducting non-recurring gains and losses was ¥2,092,945,826.67, up by 9.52% from ¥1,910,981,633.08 in 2022[15] - The net cash flow from operating activities increased by 13.84% to ¥2,726,657,097.53, compared to ¥2,395,123,454.99 in 2022[15] - The net assets attributable to shareholders of the listed company at the end of 2023 were ¥15,775,887,678.80, a 10.98% increase from ¥14,214,807,659.39 at the end of 2022[15] - Total assets as of the end of 2023 amounted to ¥32,453,092,592.42, representing a 9.61% increase from ¥29,609,041,999.59 in 2022[15] - Basic earnings per share for 2023 were RMB 2.8443, up 9.26% from RMB 2.6031 in 2022[16] - The total profit for 2023 was CNY 2.93 billion, up 9.04% year-on-year, while net profit reached CNY 2.33 billion, an increase of 9.67%[41] - The company's operating cash flow net amount was CNY 2.73 billion, reflecting a 13.84% increase compared to the previous year[42] Dividend Distribution - The company plans to distribute a cash dividend of ¥8.54 per 10 shares, totaling ¥644,345,560.29, based on a total share capital of 754,502,998 shares as of December 31, 2023[3] - For the year 2023, the company plans to distribute a cash dividend of 8.54 RMB per 10 shares, amounting to 644,345,560.29 RMB, also representing 30.03% of the net profit[119] - The company proposed a cash dividend of 7.82 RMB per 10 shares for the year 2022, totaling 590,021,344.44 RMB, which represents 30.04% of the net profit for that year[117] Research and Development - The company invested CNY 71.20 million in R&D, which is a 6.27% increase from the previous year[42] - Research and development expenses totaled ¥141,151,775.11, accounting for 0.28% of total revenue, with 49.56% of R&D costs capitalized[52] - The company is investing 500 million RMB in R&D for new technologies aimed at enhancing product efficiency[89] - Research and development investments have increased by 25%, focusing on advanced medical technologies and pharmaceuticals[90] Market Position and Strategy - The company has focused on enhancing its pharmaceutical distribution and retail sectors, maintaining a leading position in the Beijing market[23] - The company is actively promoting its "big cannabis drug" strategy to enhance supply chain management capabilities in the narcotic drug sector[25] - The company is transitioning from simple drug sales to providing comprehensive pharmaceutical solutions, improving operational efficiency through refined management[23] - The company aims to strengthen its core business and maintain market share while exploring new growth areas through strategic investments and acquisitions, focusing on high-value segments of the pharmaceutical health industry[73] - The company is actively enhancing compliance management to mitigate systemic risks and ensure adherence to regulatory requirements, which is crucial for maintaining operational integrity[73] Environmental Commitment - The company invested 31.04 million RMB in environmental protection during the reporting period[124] - The company has obtained a pollution discharge permit for its new raw material workshop, valid until August 16, 2027, focusing on managing waste gas emissions[125] - The company has established 7 pollution control facilities, all compliant with environmental regulations, and has conducted regular maintenance[128] - The company implemented a carbon reduction strategy, achieving a total reduction of 958 tons of CO2 equivalent emissions in 2023[139] - The company is committed to preventing environmental pollution through strict adherence to environmental impact assessments and management regulations[129] Governance and Compliance - The company’s governance structure is designed to ensure transparency and protect shareholder rights, with independent directors constituting over one-third of the board[76] - The company has established a comprehensive internal control management system in compliance with relevant laws and regulations, ensuring effective operational management[121] - The company has implemented a strict insider information management system to ensure the accuracy and completeness of insider information records[78] - The company is committed to maintaining compliance with regulatory requirements and has not faced penalties from securities regulatory agencies in the past three years[97] Subsidiaries and Investments - The company has a controlling interest in various subsidiaries, including Guoyao Yizhi and Guoyao Modern, with substantial shareholdings[194] - The company signed a management agreement for the 61.06% equity stake in Guorui Pharmaceutical, with a management fee of CNY 500,000 per year for a duration of three years[168] - The company plans to promote the disposal of Guorui Pharmaceutical through various means, including potential sales to independent third parties[147] Employee and Management Structure - The total number of employees in the parent company and major subsidiaries is 3,138, with 559 in the parent company and 2,579 in subsidiaries[111] - The company conducted 51 training programs in 2023, with a total of 10,196 participants and 53,683.1 training hours, achieving a 100% employee training coverage rate[114] - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 18.86 million yuan[96] - The company has seen a significant increase in executive compensation, indicating a focus on retaining top talent[87] Financial Management - The company has not reported any non-operating fund occupations or guarantees during the reporting period[149] - The company appointed PwC Zhongtian as the new accounting firm for the 2023 fiscal year, with an audit fee of RMB 840,000[153] - The audit fees for the 2023 financial report decreased by 46% compared to the previous year, which was RMB 2.3 million, due to market conditions and procurement processes[155] - The company plans to provide internal loans to its subsidiary, with a total amount not exceeding RMB 400 million, at an interest rate not lower than the LPR[162]

关于国药集团药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 目 录 1、 专项审计报告 2、 附表 委托单位：国药集团药业股份有限公司 审计单位：普华永道中天会计师事务所（特殊普通合伙） 联系电话：010-67271828 国药集团药业股份有限公司 2023 年度控股股东及其他关联方占用资金情况专项报告 및ダ e 10 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mo.jset.com.cns.cn.cn）"进行变稳。 一 国药集团药业股份有限公司 | | | 页 次 | | --- | --- | --- | | - | 控股股东及其他关联方占用资金情况专项报告 | 1 - 2 | | = | 附件: | | | | 控股股东及其他关联方占用资金情况汇总表 | 1 - 23 | 国药集团药业股份有限公司董事会: 我们审计了国药集团药业股份有限公司(以下简称"国药股份")2023 年 12 月 31 日的合并及公司资产负债表、2023年度合并及公司利润表、合并及公司股东权益变 动表、合并及公司现金流量表和财务报表附注(以下合称"财务报 ...

2023 年度控股股东及其他关联方占用资金情况专项报告 国药集团药业股份有限公司 我们审计了国药集团药业股份有限公司(以下简称"国药股份")2023 年 12 月 31 日的合并及公司资产负债表、2023年度合并及公司利润表、合并及公司股东权益变 动表、合并及公司现金流量表和财务报表附注(以下合称"财务报表")，并于 2024 年 3 月 19 日出具了报告号为普华永道中天审字(2024)第 10079 号的无保留意见审计报 告。财务报表的编制和公允列报是国药股份管理层的责任,我们的责任是在按照中 国注册会计师审计准则执行审计工作的基础上对财务报表整体发表审计意见。 在对上述财务报表执行审计的基础上,我们对后附的截至 2023年 12月 31日止 年度国药股份控股股东及其他关联方非经营性资金占用及其他关联资金往来情况汇 总表(以下简称"情况表")执行了有限保证的鉴证业务。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金往 来、对外担保的监管要求》和《公开发行证券的公司信息披露内容与格式准则第 2 号 -- 年度报告的内容与格式(2021年修订)》及上海证券交易所《上海证券交易所 上市公 ...

国药集团药业股份有限公司 关于 2023 年募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任 何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金及到账情况 经中国证券监督管理委员会于 2017 年 2 月 16 日签发的《关 于核准国药集团药业股份有限公司向国药控股股份有限公司等 发行股份购买资产并募集配套资金的批复》(证监许可[2017]219 号）核准，国药集团药业股份有限公司(以下简称"本公司""公 司")获准向国药控股股份有限公司发行 212,736,835 股股份、 向北京畅新易达投资顾问有限公司发行 11,990,013 股股份、向 北京康辰药业股份有限公司发行 20,075,116 股股份购买相关资 产，同时核准公司向境内特定投资者非公开发行不超过 41,035,851 股新股募集本次发行股份购买资产的配套资金。公 司实际非公开发行人民币普通股 41,365,452 股，每股面值人民 币 1 元，每股发行价格为人民币 24.90 元。2017 年 5 月 23 日， 独立财务顾问中国国 ...

国药集团药业股份有限公司 董事会薪酬与考核委员会实施细则 （经公司2024年3月19日第八届董事会第十五次会议审议通过) 第一章 总则 第一条 为进一步建立健全国药集团药业股份有限公司（以下简称"公司"） 董事及高级管理人员的薪酬和考核管理制度，完善公司治理结构，根据《中华人 民共和国公司法》(以下简称"《公司法》")、《上市公司治理准则》《上市公 司独立董事管理办法》《公司章程》及其他有关规定，公司设立董事会薪酬与考 核委员会，并制定本实施细则。 第二条 薪酬与考核委员会是董事会按照《公司章程》设立的专门工作机构， 主要负责制定和审查公司董事及高级管理人员的薪酬政策与方案，制定公司董事 及高级管理人员的考核标准并进行考核，对董事会负责。 第六条 薪酬与考核委员会设主任委员（召集人）一名，由独立董事委员担 任，负责主持委员会工作；在委员范围内选举产生，并报请董事会批准。 第七条 薪酬与考核委员会任期与同届董事会任期一致。委员任期届满，连 选可以连任。期间如有委员不再担任公司董事职务，自动失去委员资格，由董事 会根据《公司章程》及本实施细则规定补足委员人数。因委员辞职、被免职或其 他原因导致委员人数少于本实施细 ...